TVAMP
ALNY icon

Tennessee Valley Asset Management Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tennessee Valley Asset Management Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40
Closed -$7.66K – 147
2023
Q4 		$7.66K Buy
+40
New +$6.81K ﹤0.01% 495

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tennessee Valley Asset Management Partners's ALNY Position: Q1 2024 in Review

Tennessee Valley Asset Management Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 40 shares — an estimated $7.66K sold.

Tennessee Valley Asset Management Partners first reported a position in ALNY in Q4 2023 and held it in 1 quarter. The position peaked at $7.66K in Q4 2023. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Tennessee Valley Asset Management Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Tennessee Valley Asset Management Partners sold 40 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $7.66K.
  • Tennessee Valley Asset Management Partners first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Tennessee Valley Asset Management Partners's Alnylam Pharmaceuticals position peaked at $7.66K in Q4 2023.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Tennessee Valley Asset Management Partners's 13F filing for Q1 2024, filed 23 Apr 2024.